NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia.
Scopim-Ribeiro R, Machado-Neto JA, Eide CA, Coelho-Silva JL, Fenerich BA, Fernandes JC, Scheucher PS, Savage Stevens SL, de Melo Campos P, Olalla Saad ST, de Carvalho Palma L, de Figueiredo-Pontes LL, Simões BP, Rego EM, Tognon CE, Druker BJ, Traina F.
Scopim-Ribeiro R, et al. Among authors: simoes bp.
Invest New Drugs. 2021 Jun;39(3):736-746. doi: 10.1007/s10637-020-01028-8. Epub 2021 Jan 6.
Invest New Drugs. 2021.
PMID: 33403501